Sharma Nirmal S, Wille Keith M, Diaz Guzman Enrique
Division of Pulmonary and Critical Care Medicine, University of Alabama at Birmingham, Birmingham, Alabama - USA.
Int J Artif Organs. 2015 Mar;38(3):170-2. doi: 10.5301/ijao.5000399. Epub 2015 Mar 20.
Hepatopulmonary syndrome (HPS) is a rare complication of liver cirrhosis that may result in refractory hypoxemia even after liver transplantation. ECMO has been rarely used after liver transplantation or in patients with HPS.
We present a patient with HPS who underwent liver transplantation and developed refractory hypoxemia requiring postoperative ECMO support at our institution. During our review of literature we found nine reports of ECMO use for cardiorespiratory failure after liver transplant in the past.
Our patient had persistent intrapulmonary shunting and developed severe respiratory failure after liver transplant. Additionally, the patient was found to have an atrial septal defect (ASD) and required percutaneous closure while receiving ECMO support. Literature review suggests that survival among these patients who were supported with ECMO after liver transplant was 50% and catastrophic bleeding complications were described in only one report.
With careful selection of post-liver transplant patients and judicious management of anticoagulation, ECMO can be safely instituted in this cohort.
肝肺综合征(HPS)是肝硬化的一种罕见并发症,即使在肝移植后也可能导致难治性低氧血症。体外膜肺氧合(ECMO)在肝移植后或HPS患者中很少使用。
我们报告了一名患有HPS的患者,该患者在我们机构接受了肝移植,并出现难治性低氧血症,术后需要ECMO支持。在我们查阅文献时,我们发现过去有9篇关于ECMO用于肝移植后心肺衰竭的报告。
我们的患者在肝移植后持续存在肺内分流,并发展为严重呼吸衰竭。此外,该患者被发现患有房间隔缺损(ASD),在接受ECMO支持时需要经皮封堵。文献综述表明,这些肝移植后接受ECMO支持的患者的生存率为50%,只有一篇报告描述了灾难性出血并发症。
通过仔细选择肝移植后患者并明智地管理抗凝,ECMO可以在这一队列中安全实施。